Andrew Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, New York, NY gives an overview of the case studies on chronic lymphocytic leukemia (CLL) he presented at the 36th World Congress of the International Society of Hematology (ISH) held in Glasgow, Scotland. In the first case study, he discusses the use and side effect profiles of ibrutinib as well as idelalisib and rituximab. Dr Zelenetz also addresses the management of the side effects in his first case study. In the second case discussed, Dr Zelenetz discusses how the response to an alternative kinase inhibitor after progession is not very favorable. If the patient is intolerant to the first kinase inhibitor, the alternative kinase inhbitor can be very effective.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.